FOXO Technologies Regains SEC Compliance After Filing Form 10-Q For Quarter Ended March 31, 2024
$FOXO
Life Insurance
Finance
FOXO Technologies Regains SEC Compliance After Filing Form 10-Q For Quarter Ended March 31, 2024
Save time and jump to the most important pieces.
3 - FOXO TECHNOLOGIES INC. (0001812360) (Issuer)
3 - FOXO TECHNOLOGIES INC. (0001812360) (Issuer)
4 - FOXO TECHNOLOGIES INC. (0001812360) (Issuer)
FOXO Technologies Inc. (NYSE:FOXO) (the "Company" or "FOXO"), today announced that it has secured up to $2.8 million in Senior Notes from an institutional investor ("Investor") to fund the previously announced acquisition of Myrtle Recovery Centers, Inc. as well as provide additional working capital to support the Company's growth strategy.
FOXO Technologies Inc. (NYSE:FOXO) (the "Company"), today announced the appointment of Francis Colt deWolf to the Company's Board of Directors. Mr. deWolf III brings over 20 years of experience in the financial services Sector. He currently serves as President of Colt Capital LLC, a Florida-based company, whose principal activities focus on advising emerging market companies on private and public financing strategies. Prior to founding Colt Capital LLC, Mr. deWolf was a Senior Vice President at Oppenheimer and Company, where he oversaw a variety of financing activities. Mr. deWolf also served as Vice President at Prudential Securities and as a bond broker for Tucker Anthony. Mr. deWolf is
FOXO Technologies Inc. (NYSEAM:FOXO), a leader in commercializing epigenetic biomarkers of health and aging, today announced the resignation of Taylor Fay as Chief Operating Officer of the Company, effective April 28, 2023. "I am extremely proud of our achievements throughout Taylor's tenure at FOXO," said Tyler Danielson, interim CEO, and Chief Technology Officer at FOXO. "His leadership and work ethic inspired those around him, and we are a more talented and dedicated team because of his contributions. The Board and executive leadership thank Taylor for his leadership and wish him well in his future endeavors." "Throughout my tenure at FOXO, I have worked alongside an exceptional team
SC 13G/A - FOXO TECHNOLOGIES INC. (0001812360) (Subject)
SC 13D/A - FOXO TECHNOLOGIES INC. (0001812360) (Subject)
SC 13D - FOXO TECHNOLOGIES INC. (0001812360) (Subject)
10-Q - FOXO TECHNOLOGIES INC. (0001812360) (Filer)
8-K - FOXO TECHNOLOGIES INC. (0001812360) (Filer)
DEFR14A - FOXO TECHNOLOGIES INC. (0001812360) (Filer)
MINNEAPOLIS, MN, Nov. 18, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE:FOXO) (the "Company" or "FOXO"), will hold a Special Meeting of its Shareholders at 10.30am EST on Friday, November 29, 2024. The Board of Directors of the Company has authorized a virtual meeting of its shareholders (the "Special Meeting") to be held on Friday, November 29, 2024, at 10:30 a.m. Eastern Standard Time to approve several proposals. The record date was November 15, meaning that all shareholders of record on November 15, 2024, will be entitled to vote on the approvals requested. The Company has several approvals it requires from its shareholders as a result of transactions entered into and plans t
MINNEAPOLIS, MN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company" or "FOXO"), provides a shareholder letter from Mark White, Interim CEO of FOXO, on what has been achieved in 2024 and what is planned for the remainder of 2024 and beyond. Dear Fellow Shareholders, 2024 has been an exciting, tumultuous and productive year for us. We believe the accomplishments already completed and that we believe will be achieved before year-end create a foundation from which we can build a successful enterprise that will increase shareholder value. The Company began 2024 with a continued focus on commercializing its epigenetic technology while, at the same ti
MINNEAPOLIS, MN, Sept. 17, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), today announced it has completed the acquisition of the second revenue-generating operation from Rennova Health, Inc. (OTC:RNVA) ("Rennova"). The Company had previously announced it had entered into two share exchange agreements with Rennova. The first agreement was to acquire the equity in Myrtle Recovery Centers, Inc., Rennova's behavioral health services subsidiary. Closing of the Myrtle transaction occurred on June 14, 2024. The second agreement was to acquire the equity in Rennova Community Health, Inc. (RCHI), the owner of Scott County Community Hospital, I
MINNEAPOLIS, MN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company" or "FOXO"), provides a shareholder letter from Mark White, Interim CEO of FOXO, on what has been achieved in 2024 and what is planned for the remainder of 2024 and beyond. Dear Fellow Shareholders, 2024 has been an exciting, tumultuous and productive year for us. We believe the accomplishments already completed and that we believe will be achieved before year-end create a foundation from which we can build a successful enterprise that will increase shareholder value. The Company began 2024 with a continued focus on commercializing its epigenetic technology while, at the same ti
MINNEAPOLIS, MN, Sept. 17, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), today announced it has completed the acquisition of the second revenue-generating operation from Rennova Health, Inc. (OTC:RNVA) ("Rennova"). The Company had previously announced it had entered into two share exchange agreements with Rennova. The first agreement was to acquire the equity in Myrtle Recovery Centers, Inc., Rennova's behavioral health services subsidiary. Closing of the Myrtle transaction occurred on June 14, 2024. The second agreement was to acquire the equity in Rennova Community Health, Inc. (RCHI), the owner of Scott County Community Hospital, I
MINNEAPOLIS, MN, Aug. 08, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the "Company"), today announced that its recently acquired subsidiary, Myrtle Recovery Centers, Inc. ("Myrtle"), has been granted two full licenses from the Tennessee Department of Mental Health and Substance Abuse Services, effective August 1, 2024, for 12 months. The first license authorizes the provision of services for alcohol and drug residential detoxification treatment, as well as alcohol and drug residential rehabilitation treatment. The second license authorizes the provision of services for non-residential office-based opiate treatment. FOXO completed the acquisition of Myrtle re